Benzinga | Nov 18, 2020 05:11PM EST

Tang Capital Partners Says We Are Pleased To Submit A Proposal To Acquire The Remaining Common Stock Of Aptevo Therapeutics That TCP Does Not Already Own For A Price Of $50/Share In Cash

-SEC Filing